Pharmaceutical company MSD (known as 'Merck & Co' in the US) has urged a federal court to rule that its new vaccine doesn’t infringe three patents owned by Pfizer’s subsidiary, Wyeth, because they are invalid.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
28 September 2021 Pfizer subsidiary Anacor has filed five lawsuits targeting drug manufacturers looking to manufacture generic versions of its eczema treatment Eucrisa.
31 May 2022 Pfizer has announced that it will provide all of its current and future patent-protected medicines and vaccines—that are available in the US or EU—on a not-for-profit basis to 45 lower-income countries.
9 June 2022 Pfizer has sued MSN Laboratories to prevent the rollout of generic copies of the blockbuster drug Xeljanz, used to treat patients with arthritis.
28 September 2021 Pfizer subsidiary Anacor has filed five lawsuits targeting drug manufacturers looking to manufacture generic versions of its eczema treatment Eucrisa.
31 May 2022 Pfizer has announced that it will provide all of its current and future patent-protected medicines and vaccines—that are available in the US or EU—on a not-for-profit basis to 45 lower-income countries.
9 June 2022 Pfizer has sued MSN Laboratories to prevent the rollout of generic copies of the blockbuster drug Xeljanz, used to treat patients with arthritis.
28 September 2021 Pfizer subsidiary Anacor has filed five lawsuits targeting drug manufacturers looking to manufacture generic versions of its eczema treatment Eucrisa.
31 May 2022 Pfizer has announced that it will provide all of its current and future patent-protected medicines and vaccines—that are available in the US or EU—on a not-for-profit basis to 45 lower-income countries.
9 June 2022 Pfizer has sued MSN Laboratories to prevent the rollout of generic copies of the blockbuster drug Xeljanz, used to treat patients with arthritis.
